ArticleThe EMBO journal2002
Suppression of the STK15 oncogenic activity requires a transactivation-independent p53 function.
Article in The EMBO journal, 2002. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed, 110 citations in OpenAlex.
- Deubiquitinase-Targeting Chimeras (DUBTACs) as a Potential Paradigm-Shifting Drug Discovery Approach.Journal of medicinal chemistry · 2025Review
- TF-DUBTACs Stabilize Tumor Suppressor Transcription Factors.Journal of the American Chemical Society · 2022Article
- CF-PPiD technology based on cell-free protein array and proximity biotinylation enzyme for in vitro direct interactome analysis.Scientific reports · 2022Article
- Editorial: Genetics and Molecular Mechanisms of Oral and Esophageal Squamous Cell Carcinoma.Frontiers in oncology · 2022Article
- AURKA Increase the Chemosensitivity of Colon Cancer Cells to Oxaliplatin by Inhibiting the TP53-Mediated DNA Damage Response Genes.BioMed research international · 2020Article
- Targeted therapies for non-HPV-related head and neck cancer: challenges and opportunities in the context of predictive, preventive, and personalized medicine.The EPMA journal · 2019Review
- A Network-guided Association Mapping Approach from DNA Methylation to Disease.Scientific reports · 2019Article
- Identification of key candidate genes and pathways in hepatocellular carcinoma by integrated bioinformatical analysis.Experimental and therapeutic medicine · 2018Article
- Antitumor activity of the aurora a selective kinase inhibitor, alisertib, against preclinical models of colorectal cancer.Oncotarget · 2016Article
- Aurora Kinase A expression predicts platinum-resistance and adverse outcome in high-grade serous ovarian carcinoma patients.Journal of ovarian research · 2016Article
- Functional Significance of Aurora Kinases-p53 Protein Family Interactions in Cancer.Frontiers in oncology · 2016Review
- Alisertib Induces Cell Cycle Arrest, Apoptosis, Autophagy and Suppresses EMT in HT29 and Caco-2 Cells.International journal of molecular sciences · 2015Article
- Aurora kinase A has a significant role as a therapeutic target and clinical biomarker in endometrial cancer.International journal of oncology · 2015Article
- Issues in interpreting the in vivo activity of Aurora-A.Expert opinion on therapeutic targets · 2015Review
- Aurora-A: a potential DNA repair modulator.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2014Review
- Update on anaplastic thyroid carcinoma: morphological, molecular, and genetic features of the most aggressive thyroid cancer.International journal of endocrinology · 2014Review
- Aurora kinases in head and neck cancer.The Lancet. Oncology · 2013Review
- Telmisartan exerts pleiotropic effects in endothelial cells and promotes endothelial cell quiescence and survival.Arteriosclerosis, thrombosis, and vascular biology · 2013Article
- Aurora A kinase (AURKA) in normal and pathological cell division.Cellular and molecular life sciences : CMLS · 2013Review
- p53-Aurora A mitotic feedback loop regulates cell cycle progression and genomic stability.Cell cycle (Georgetown, Tex.) · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Using a transactivation-defective p53 derivative as bait, STK15, a centrosome-associated oncogenic serine/threonine kinase, was isolated as a p53 partner. The p53-STK15 interaction was confirmed further by co-immunoprecipitation and GST pull-down studies. In co-transfection experiments, p53 suppressed STK15-induced centrosome amplification and cellular transformation in a transactivation-independent manner. The suppression of STK15 oncogenic activity by p53 might be explained in part by the finding that p53 inhibited STK15 kinase activity via direct interaction with the latter's Aurora box. Taken together, these findings revealed a novel mechanism for the tumor suppressor function of p53.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.